Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia.
Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, den Boer ML, Kuiper RP, Moorman AV, Boer JM, van Leeuwen FN. Østergaard A, et al. Among authors: hoogerbrugge pm. Hemasphere. 2023 May 4;7(5):e875. doi: 10.1097/HS9.0000000000000875. eCollection 2023 May. Hemasphere. 2023. PMID: 37153875 Free PMC article.
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia.
Vervoort BMT, Butler M, Grünewald KJT, Schenau DSVI, Tee TM, Lucas L, Huitema ADR, Boer JM, Bornhauser BC, Bourquin JP, Hoogerbrugge PM, Van der Velden VHJ, Kuiper RP, Van der Meer LT, Van Leeuwen FN. Vervoort BMT, et al. Among authors: hoogerbrugge pm. Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284357. Online ahead of print. Haematologica. 2024. PMID: 38841778 Free article.
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, Bierings M, van den Bos C, de Haas V, Hoogerbrugge PM, Tissing WJE, Veening MA, Pieters R. van der Sluis IM, et al. Among authors: hoogerbrugge pm. J Clin Oncol. 2024 May 10;42(14):1676-1686. doi: 10.1200/JCO.23.01797. Epub 2024 Feb 2. J Clin Oncol. 2024. PMID: 38306592 Free PMC article. Clinical Trial.
Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.
Antić Ž, Yu J, Bornhauser BC, Lelieveld SH, van der Ham CG, van Reijmersdal SV, Morgado L, Elitzur S, Bourquin JP, Cazzaniga G, Eckert C, Camós M, Sutton R, Cavé H, Moorman AV, Sonneveld E, Geurts van Kessel A, van Leeuwen FN, Hoogerbrugge PM, Waanders E, Kuiper RP. Antić Ž, et al. Among authors: hoogerbrugge pm. Pediatr Blood Cancer. 2022 Jan;69(1):e29361. doi: 10.1002/pbc.29361. Epub 2021 Oct 1. Pediatr Blood Cancer. 2022. PMID: 34597466 Free article.
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.
Antić Ž, Yu J, Van Reijmersdal SV, Van Dijk A, Dekker L, Segerink WH, Sonneveld E, Fiocco M, Pieters R, Hoogerbrugge PM, Van Leeuwen FN, Van Kessel AG, Waanders E, Kuiper RP. Antić Ž, et al. Among authors: hoogerbrugge pm. Haematologica. 2021 Dec 1;106(12):3046-3055. doi: 10.3324/haematol.2020.259226. Haematologica. 2021. PMID: 33147938 Free PMC article.
146 results